SCHEMBL6486936

SCHEMBL6486936

O=C(O)CNc1ccc(CCCc2ccccc2Nc2ccccc2C(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.48
RECQL P46063 1/20 0.48
BLM P54132 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
PLK1 P53350 4/20 0.46
FABP4 P15090 2/20 0.46
SIRT2 Q8IXJ6 1/20 0.45
CLCN2 P51788 1/20 0.44
SLC16A3 O15427 3/20 0.42
PLK3 Q9H4B4 3/20 0.42
CDC25B P30305 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
POLB P06746 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FABP3 P05413 1/20 0.41
FABP5 Q01469 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485787 0.85 MEN1 (0.64) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6486927 0.78 CLCN2 (0.46) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6475710 0.78 CLCN2 (0.49) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6483326 0.78 MEN1 (0.58) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6481725 0.76 MEN1 (0.62) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6482028 0.76 PLK1 (0.57) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6474416 0.75 SIRT2 (0.62) MEN1RECQLBLMKMT2ATDP1
SCHEMBL6475772 0.74 MEN1 (0.76) MEN1RECQLBLMKMT2ATDP1
SCHEMBL3555545 0.74 SLC16A3 (0.50) PLK1SLC16A3PLK3KDM4E
SCHEMBL6482855 0.73 SIRT2 (0.77) MEN1RECQLBLMKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6972287-B1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits PFIZER INC. (US) 2005-12-06 US disclosed
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits AUGELLI-SZAFRAN CORINNE ELIZAB (US) 2004-11-04 US disclosed
EP-1225886-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2002-07-31 EP disclosed
WO-2000076489-A2 METHOD OF INHIBITING AMYLOID PROTEIN AGGREGATION AND IMAGING AMYLOID DEPOSITS WARNER-LAMBERT COMPANY (US) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220235-A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits APP, PSEN1, BACE1 MEN1 474/4885RECQL 1257/4885BLM 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.